A rare case of type 1 citrullinemia in newborn

Authors

  • Ashutosh Singh Rathore Department of Pediatrics, Smt. B. K. S Medical Institute and Research Center, Sumandeep Vidhyapeeth Deemed to be University, Wagodhiya, Vadodara, Gujarat, India
  • Guntupalli Shravya L. Department of Pediatrics, Smt. B. K. S Medical Institute and Research Center, Sumandeep Vidhyapeeth Deemed to be University, Wagodhiya, Vadodara, Gujarat, India
  • Dhrumika Seth Department of Pediatrics, Smt. B. K. S Medical Institute and Research Center, Sumandeep Vidhyapeeth Deemed to be University, Wagodhiya, Vadodara, Gujarat, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20221079

Keywords:

Citrullinemia, ASS enzyme, IEM

Abstract

Citrullinemia type I (CTLN1) is a rare and lethal autosomal recessive genetic disorder. CTLN1 is caused by deficiency or absence of the enzyme arginino succinate synthetase (ASS). We reported a rare case of CTLN1 in a male full-term neonate. This report related to a full-term male child, born out of 3rd degree consanguineous marriage, admitted at our unit on DOL-3 with severe dehydration. ABG showed persistent severe metabolic acidosis despite of adequate treatment. So, suspecting an inborn error of metabolism (IEM) investigations were done in which we found high serum ammonia, serum lactate and urinary sodium. TMS and GCMS were done which observed a profile which can be seen in case of citrullinemia. CTLN1 is a rare and lethal genetic disorder. High index of suspicion is needed when patients present with such complex symptoms. Diagnosing and timely intervention helps in reducing the morbidity and mortality and with treatment, people with citrullinemia type 1 can have normal growth and development.

Author Biography

Guntupalli Shravya L., Department of Pediatrics, Smt. B. K. S Medical Institute and Research Center, Sumandeep Vidhyapeeth Deemed to be University, Wagodhiya, Vadodara, Gujarat, India

Junior Resident

Department of Pediatrics

References

Sander J, Janzen N, Sander S, Steuerwald U, Das AM, Scholl S, et al. Neonatal screening for citrullinemia. Eur J Pediatr. 2003;162(6):417-20.

Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.

Bachman C. Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur J Paediatr. 2003;162(6):410-6.

Bachman C. Long term outcome of patients with urea cycle disorders and the question of neonatal screening. Eur J Pediatr. 2003;162(1):29-33.

Korea Disease Control and Prevention Agency. Rare disease information citrullinemia. Cheongju Korea Dis Control Prevent Agency. 2021.

Chong MF, Shaw V, M. Lawson. Clinical Paediatric Dietetics. Oxford: Blackwell Publishing; 2007: 604.

Citrullinemia. Screening, Technology and Research in Genetics (STAR-G). Updated Feb. 18, 2016

Citrullinemia type 1. National Organization for Rare Disorders (NORD).

Quinonex SC, Thoene JG. Citrullinemia type I. Gene Reviews. Seattle (WA): University of Washington; 1993.

Wasim M, Awan FR, Khan HN, Tawab A, Iqbal M, Ayesha H. Aminoacidopathies: prevalence, etiology, screening, and treatment options. Biochem Genet. 2018;56(1-2):7-21.

Downloads

Published

2022-04-25

Issue

Section

Case Reports